Filing Alert: Omega Therapeutics Chapter 11

Omega Therapeutics, Inc., a Cambridge, MA-based biotechnology company, filed for Chapter 11 protection on Feb. 10 in the U.S. Bankruptcy Court for the District of Delaware.

The company reports $137.5 million in assets and $140.4 million in liabilities. The filing indicates that there will be funds available for distribution to unsecured creditors. The case number is 25-10211.

Top Unsecured Claims

Key Parties

General Bankruptcy Counsel:

• Derek C. Abbott
• Morris, Nichols, Arsht & Tunnell LLP
• Email: dabbott@morrisnichols.com

Special Counsel:

• Latham & Watkins LLP

Restructuring Advisor:

• Triple P RTS, LLC (Portage Point)

Investment Banker:

• Triple P Securities, LLC (Portage Point)

Claims Agent:

• Kroll Restructuring Administration LLC

Signatories:

• Jeffrey T. Varsalone – Independent Restructuring Expert Director

Equity Security Holders:

• Cede & Co. – 50.2% Equity Interest
• Flagship Pioneering Fund VI, L.P. – 15.2% Equity Interest
• Flagship Ventures Fund V, L.P. – 10.6% Equity Interest
• Flagship Pioneering Special Opportunities Fund II, L.P. – 8.8% Equity Interest
• Flagship VentureLabs V, L.L.C – 4.0% Equity Interest
• State of Wisconsin Investment Board – 3.0% Equity Interest
• FPN, L.P. – 2.4% Equity Interest
• Flagship V VentureLabs Rx Fund, L.P. – 2.0% Equity Interest
• Nutritional Health LTP Fund, L.P. – 1.8% Equity Interest
• Richard A. Young – 1.3% Equity Interest
• Point72 Biotech Private Investments, LLC – 0.6% Equity Interest
• Mahesh Karande – 0.2% Equity Interest

Bondoro Insights is continuing to monitor this case and will provide further coverage as appropriate.

Stay informed on every Chapter 11 bankruptcy case with liabilities exceeding $10 million. Subscribe for free to have our coverage delivered directly to your inbox, and explore our full archive of past summaries.

If you’re already a subscriber and would like to receive timely filing alerts, please reach out and we’ll add you to the distribution list.